Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer
A Randomized, Double Blind, Placebo-Controlled Phase II Study of Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer
Sponsor: Solvay Pharmaceuticals
Terminated
This study has been terminated due to poor accrual
Other terminated trials from Solvay Pharmaceuticals
- Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism · Phase NA · Oct 2018
- Acute Decompensated Heart Failure; Renal Dysfunction · Phase PHASE2 · Jan 2010
- Obsessive Compulsive Disorder · Phase PHASE4 · Apr 2009
- Hyper-Triglyceridemia · Phase PHASE4 · Mar 2009
- Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis · Phase PHASE2 · Mar 2009
Other Prostate Cancer trials with similar outcome
This PHASE2 trial investigates Prostate Cancer and is currently terminated or withdrawn. Solvay Pharmaceuticals leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Solvay Pharmaceuticals
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .